R(
Organon Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Elyea™ (etonogestrel/ethinyl estradiol vaginal system) | Contraception | Approved |
| APR-TD (Annual Performer Ring) | Contraception | Development |
| Phexxi® | Contraception | Approved |
| Esmya® (ulipristal acetate) | Uterine Fibroids | Approved |
| Renflexis® (infliximab biosimilar) | Immunology (e.g., RA, Crohn's) | Approved |
| Brenzys® (etanercept biosimilar) | Immunology (e.g., RA, Psoriasis) | Approved |
| Aybintio® (bevacizumab biosimilar) | Oncology | Approved |
| MK-1293 (insulin glargine biosimilar) | Diabetes | Approved/Filed |
Leadership Team at Organon
KA
Kevin Ali
Chief Executive Officer
MW
Matthew Walsh
Chief Financial Officer
SM
Sandra Milligan, M.D., J.D.
Head of Research & Development and Chief Medical Officer
SF
Susanne Fiedler
Chief Commercial Officer
DT
Deborah Telman
Executive Vice President, General Counsel and Corporate Secretary
RR
Ronald Rogers
Executive Vice President, Global Human Resources
JC
Juan Camilo Arjona
Executive Vice President, Chief Strategy and Business Development Officer
R(
Robert (Bob) Ashe
Executive Vice President, Manufacturing and Supply
CS
Carrie S. Cox
Chair of the Board
J(
Joseph (Joe) C. Papa
Director